RxDoctor Payments Data

Daniel Muller, MD

Rheumatology · Fort Collins, CONPI 1073589016

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $3,150 of the $4,600 with a category attached, or 68.5%. Amgen accounts for 71.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $4,049 and has fallen 97.8% since, to $88 in 2024.

$4,600in general payments, 2019–2025

Across 18 payments — averaging $255.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • Regeneron Healthcare Solutions, Inc.$603
  • AstraZeneca$359
  • Sanofi$191
  • Lilly USA, LLC$98
  • E.r. Squibb & Sons, L.L.C.$84

What the payments were for

  • Speaking & faculty fees$3,15068%
  • Travel & lodging$702%
  • Food & beverage$1,38030%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,600 in reported general payments places this provider in the 70th percentile of 108 rheumatology providers in Colorado.

See all rheumatology providers in Colorado

Medicare billing

Part B allowed, 2024
$561,516
Medicare patients
290
Services billed
24,945

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab90$752,343
Enbrel SureclickEtanercept25$233,656
XeljanzTofacitinib Citrate33$209,306
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$173,506
EnbrelEtanercept14$149,483
Xeljanz XrTofacitinib Citrate18$147,424
Taltz AutoinjectorIxekizumab13$98,341
HumiraAdalimumab11$75,859
BenlystaBelimumab14$64,950
OtezlaApremilast13$62,422
Orencia ClickjectAbatacept11$62,039
Actemra ActpenTocilizumab14$32,044
Hydroxychloroquine Sulfate279$13,768
MethotrexateMethotrexate Sodium242$6,832
Prednisone530$6,328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla$3,264$211,90527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 108 rheumatology providers in Colorado.

Other rheumatology in Fort Collins

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →